Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 21565902)


Sirolimus demonstrates activity in the primary therapy of acute graft-versus-host disease without systemic glucocorticoids.

Pidala J, Tomblyn M, Nishihori T, Field T, Ayala E, Perkins J, Fernandez H, Locke F, Perez L, Ochoa JL, Alsina M, Anasetti C.

Haematologica. 2011 Sep;96(9):1351-6. doi: 10.3324/haematol.2011.041236. Epub 2011 May 12.


[Etanercept on steroid-refractary acute graft-versus-host disease].

González Munguía S, Pérez León M, Piñero González M, Díaz Pestano MM, Molero Gómez R, Luzardo Henríquez HD.

Farm Hosp. 2015 May 1;39(3):147-51. doi: 10.7399/fh.2015.39.3.8000. Spanish.


[Sirolimus associated pneumonitis in a hematopoietic stem cell transplant patient].

García E, Buenasmañanas D, Martín C, Rojas R.

Med Clin (Barc). 2015 Jul 6;145(1):21-3. doi: 10.1016/j.medcli.2015.02.025. Epub 2015 May 12. Spanish.


Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.

Pidala J, Kim J, Alsina M, Ayala E, Betts BC, Fernandez HF, Field T, Jim H, Kharfan-Dabaja MA, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona L, Perez L, Riches M, Anasetti C.

Haematologica. 2015 Jul;100(7):970-7. doi: 10.3324/haematol.2015.123588. Epub 2015 Apr 3.


Recent topics in graft-versus-host disease: from the perspectives of pathogenesis and treatment.

Murata M.

Int J Hematol. 2015 May;101(5):426-7. doi: 10.1007/s12185-015-1789-x. Epub 2015 Apr 2. No abstract available.


Comparative study of modification of the osmolarity in graft versus host disease.

García-Delpech S, Hervás Ontiveros A, Soler M, Udaondo P, Cisneros-Lanuza Á.

Arch Soc Esp Oftalmol. 2015 Mar 25. pii: S0365-6691(15)00047-7. doi: 10.1016/j.oftal.2015.02.004. [Epub ahead of print] English, Spanish. No abstract available.


Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease.

Palmer J, Chai X, Martin PJ, Weisdorf D, Inamoto Y, Pidala J, Jagasia M, Pavletic S, Cutler C, Vogelsang G, Arai S, Flowers ME, Lee SJ.

Haematologica. 2015 May;100(5):690-5. doi: 10.3324/haematol.2014.117283. Epub 2015 Feb 24.


Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial.

Mielcarek M, Furlong T, Storer BE, Green ML, McDonald GB, Carpenter PA, Flowers ME, Storb R, Boeckh M, Martin PJ.

Haematologica. 2015 Jun;100(6):842-8. doi: 10.3324/haematol.2014.118471. Epub 2015 Feb 14.


Automated red blood cell exchange for acute drug removal in a patient with sirolimus toxicity.

Galera P, Martin HC, Welch L, Sulmasy P, Cerny J, Greene M, Vauthrin M, Bailey JA, Weinstein R.

J Clin Apher. 2015 Jan 24. doi: 10.1002/jca.21381. [Epub ahead of print]


2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series.

Pavletic SZ, Vogelsang GB, Lee SJ.

Biol Blood Marrow Transplant. 2015 Mar;21(3):387-8. doi: 10.1016/j.bbmt.2014.12.035. Epub 2015 Jan 5. No abstract available.


Thromboelastometry-guided therapy of massive gastrointestinal bleeding in a 12-year old boy with severe Graft-versus-Host disease.

Spiezia L, Mazza A, Pelizzaro E, Campello E, Messina C, Pettenazzo A, Simioni P.

Blood Transfus. 2015 Apr;13(2):320-3. doi: 10.2450/2014.0031-14. Epub 2014 Sep 12. No abstract available.


Disease severity in chronic graft-versus-host disease: doctors' gut feeling versus biostatistics?

Socié G.

Haematologica. 2014 Oct;99(10):1534-6. doi: 10.3324/haematol.2014.113878. No abstract available.


Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure.

Das-Gupta E, Greinix H, Jacobs R, Zhou L, Savani BN, Engelhardt BG, Kassim A, Worel N, Knobler R, Russell N, Jagasia M.

Haematologica. 2014 Nov;99(11):1746-52. doi: 10.3324/haematol.2014.108217. Epub 2014 Aug 22.


Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease.

Inamoto Y, Martin PJ, Storer BE, Palmer J, Weisdorf DJ, Pidala J, Flowers ME, Arora M, Jagasia M, Arai S, Chai X, Pavletic SZ, Vogelsang GB, Lee SJ; Chronic GVHD Consortium.

Haematologica. 2014 Oct;99(10):1618-23. doi: 10.3324/haematol.2014.109611. Epub 2014 Jul 4.


Oral features of graft-versus-host disease.

Torres SR.

Rev Bras Hematol Hemoter. 2014;36(1):9-11. doi: 10.5581/1516-8484.20140005. No abstract available.


[Delayed wound healing during therapy of cutaneous graft-versus-host disease with everolimus].

Brown A, Neumayer D, Rafieé-Tari Z, Krieg T, Eming SA.

Hautarzt. 2014 Jun;65(6):553-5. doi: 10.1007/s00105-014-2762-y. German.


Nodular regenerative hyperplasia causing portal hypertension in a patient with chronic graft versus host disease: response to sirolimus.

Choe H, Aldoss I, Chaudhary P, Donovan J, Petrovic L, Pullarkat V.

Acta Haematol. 2014;132(1):49-52. doi: 10.1159/000356736. Epub 2014 Jan 15. Review. No abstract available.


Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial.

Jim HS, Barata A, Small BJ, Jacobsen PB, Pidala J.

Haematologica. 2014 Mar;99(3):548-53. doi: 10.3324/haematol.2013.088781. Epub 2013 Nov 15.


Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure.

Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, Lin TY, Kuo HP.

Crit Care Med. 2014 Feb;42(2):313-21. doi: 10.1097/CCM.0b013e3182a2727d.


Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease.

Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA.

Haematologica. 2014 Feb;99(2):385-91. doi: 10.3324/haematol.2013.093062. Epub 2013 Sep 20.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk